Harrow, Inc. has announced impressive financial results for the third quarter of 2026, showcasing a record revenue of $99.3 million. This figure represents a 41% increase from the previous quarter and a 39% rise compared to the same period last year. The growth highlights the company’s strong performance in the pharmaceutical preparations sector, particularly in its branded products.

The announcement, made on November 9, 2026, is significant as it underscores Harrow's position as a leading provider of ophthalmic disease management solutions in North America. The company’s revenues were primarily driven by branded product sales, which accounted for $83.5 million, or approximately 84% of total revenue, reflecting a 62% year-over-year increase.

According to the filing, Harrow's GAAP net income for the quarter was $9.8 million, a notable turnaround from a net loss of $17.3 million in the second quarter of 2026. This improvement was aided by a $5 million gain from a litigation settlement. Additionally, the company reported an adjusted EBITDA of $21.2 million, compared to a loss of $1.2 million in the previous quarter.

Mark L. Baum, Chairman and CEO of Harrow, expressed optimism about the company’s trajectory, stating, "The third quarter delivered the second-half acceleration we anticipated. Branded products drove record revenue, growing 62% year over year." He emphasized the importance of maintaining this momentum into the fourth quarter, which he expects to be the strongest on record for Harrow.

Harrow reaffirmed its full-year revenue guidance of $350 million to $365 million and updated its adjusted EBITDA guidance to more than $40 million. Baum noted that achieving this guidance would require strong execution, particularly in light of the company’s recent investments aimed at accelerating its G-MELT NDA submission and integrating new products.

In terms of product performance, Harrow saw significant growth in its key offerings. VEVYE, for instance, generated record revenue of $39.7 million, up 75% year over year, while TRIESENCE also delivered strong results. The company highlighted that IHEEZO unit demand grew 21% year over year, showcasing the effectiveness of its expanded sales force.

The filing indicates that Harrow continues to position itself favorably within the pharmaceutical preparations industry, with its innovative product lines and strategic growth initiatives. This strong performance may compel competitors to enhance their own offerings and strategies to keep pace with Harrow's success.

Looking ahead, Harrow has not disclosed specific next steps beyond its earnings guidance and product development plans. However, the company’s recent performance suggests a proactive approach to maintaining its growth trajectory.

Details were not available in the SEC filing regarding any upcoming votes or additional filings.